woman in library 1420X500

The results of recent clinical trials signal a shifting treatment paradigm that moves away from chemotherapy and crizotinib toward next-generation ALK inhibitors as first line therapy for patients with advanced ALK-positive NSCLC.

These results might mean a new standard of care for previously untreated patients with ALK-positive NSCLC.

Learn More